Financial Results for the 2nd Quarter of the Year Ending March 31, 2014 <Supplement>

As of October 30, 2013

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for the 2nd Quarter of FY2013 Ending March 31, 2014 and Forecasts for FY2013

(Amounts less than ¥ 100 million are rounded.)

1. Summary of Financial Results for the 2nd Quarter of FY2013

[Billion yen]

Net Sales	202.8	Y-on-Y	(1.0)	(0.5 %)
Pharmaceuticals	202.1	Y-on-Y	1.3	0.7 %
Other Businesses	0.8	Y-on-Y	(2.3)	(74.9 %)

In the pharmaceuticals segment, net sales were ¥202.1 billion, up 0.7%, or ¥1.3 billion, year-on-year.
In the domestic sales of ethical drugs, favorable sales growth was recorded by Remicade, an anti-TNF α monoclonal antibody and other new drugs. However, there were the growing impact of generics and the cancellation of alliance in generics. As a result, the domestic sales of ethical drugs decreased 3.2%, year-on-year, to ¥171.0 billion.
Overseas sales of ethical drugs increased 2.6%, year-on-year, to ¥10.4 billion, and sales of OTC products decreased 13.4%, year-on-year, to ¥2.4 billion.
Sales of others in pharmaceuticals increased 63.5%, year-on-year, to ¥18.2 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis.
In others, sales decreased 74.9%, or ¥2.3 billion, year-on-year, due to the transfer of fine chemical operations in July 2012.

The Principal Products and Businesses in Each Business Segment
Pharmaceuticals: Ethical drugs, over-the-counter-drugs
Other businesses: Fine chemicals, real-estate leasing, information services, advertising, etc

[Billion yen]

Operating Income	30.5	Y-on-Y	(1.8)	(5.5 %)

Operating income decreased 5.5%, or ¥1.8 billion, year-on-year, to ¥30.5 billion.
Gross profit decreased ¥4.1 billion, year-on-year, to ¥120.4 billion because plasma fractionation products were changed from the own products to other company's products after the integration of the plasma fractionation operations in October 2012.
The cost of sales ratio worsened by 1.7 percentage points, year-on-year.
SG&A expenses decreased ¥2.4 billion, year-on-year, to ¥90.0 billion, due to the decrease in expenses related to the plasma faractionation operations caused by the above integration. R&D expenses were ¥34.3 billion, accounting for 16.9% of net sales.

[Billion yen]

Ordinary Income	32.2	Y-on-Y	(0.9)	(2.8 %)
Net Income	28.5	Y-on-Y	9.1	46.4 %

Ordinary income was down 2.8%, or ¥0.9 billion, year-on-year, to ¥32.2 billion, and net income was up 46.4%, or ¥9.1 billion, year-on-year, to ¥28.5 billion.
Extraordinary income was ¥11.9 billion, including profit on arbitration award. In the previous fiscal year, the Company recorded extraordinary income of ¥1.2 billion, such as gain on sales of property, plant and equipment.
Extraordinary loss was ¥0.9 billion, including loss on impairment of fixed assets. In the previous fiscal year, the Company recorded extraordinary loss of ¥3.6 billion, such as loss on business integration.

2. Summary of Forecasts for FY2013

[Billion yen]

Net Sales	419.0	Y-on-Y	(0.2)	0.0 %
Operating Income	63.0	Y-on-Y	(6.0)	(8.7 %)
Ordinary Income	65.5	Y-on-Y	(3.9)	(5.6 %)
Net Income	45.0	Y-on-Y	3.1	7.4 %

3. Dividends

	FY2013 (Estimate)		FY2012	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	20	40	20	40
Dividends Payout Ratio	-	49.9%	-	53.6%
prior to amortization of goodwill	-	40.8%	-	43.2%

2 Consolidated Financial Indicators for the 2nd Quarter of FY2013

(Amounts less than ¥100 million are rounded.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	1st Half of FY2013	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2012	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %
Net sales	**202.8**	203.8	(1.0)	(0.5)	200.0	2.8	1.4
Cost of sales	**82.4**	79.3	3.2	4.0	78.0	4.4	5.7
Sales cost ratio	**40.6%**	38.9%			39.0%		
Gross operation profit	**120.4**	124.6	(4.1)	(3.3)	122.0	(1.6)	(1.3)
SG&A expenses	**90.0**	92.3	(2.4)	(2.6)	92.0	(2.0)	(2.2)
% of net sales	**44.4%**	45.3%			46.0%		
Operating income	**30.5**	32.2	(1.8)	(5.5)	30.0	0.5	1.5
Ordinary income	**32.2**	33.1	(0.9)	(2.8)	31.0	1.2	3.9
Extraordinary income and loss	**11.1**	(2.4)	13.5	-	10.0	1.1	-
Net income	**28.5**	19.5	9.1	46.4	26.0	2.5	9.8

Forecasts for extraordinary income and loss and net income were revised on September 25;
extraordinary income and loss, (¥0.1 billion) → ¥10.0 billion, net income, ¥19.0 billion → ¥26.0 billion

(2) Sales by Business Segments

[Billion yen]

	1st Half of FY2013	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2012	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Pharmaceuticals	**202.1**	200.7	1.3	0.7	199.3	2.8	1.4	Ethical drugs domestic sales (5.6) Ethical drugs overseas sales 0.3 Contracted manufacturing products (0.8) Licensing fee, etc. 7.9 OTC drugs (0.4) See "Sales of Main Products"on page 5.
% Composition	**99.6%**	98.5%			99.7%			
Domestic	**176.4**	183.4	(6.9)	(3.8)	175.7	0.7	0.4	
Overseas	**25.6**	17.4	8.2	47.4	23.6	2.0	8.6	
Others	**0.8**	3.1	(2.3)	(74.9)	0.7	0.1	10.7	Decrease due to transfer of fine chemical operations
% Composition	**0.4%**	1.5%			0.4%			
Domestic	**0.2**	2.0	(1.8)	(88.1)	0.2	0.0	21.0	
Overseas	**0.5**	1.1	(0.5)	(49.6)	0.5	0.0	6.6	
Total	**202.8**	203.8	(1.0)	(0.5)	200.0	2.8	1.4	Overseas sales ratio 1st half of FY2012: 9.0% 1st half of FY2013: 12.9% Average exchange rate 1st half of FY2012: 1$= ¥79.78 1st half of FY2013: 1$= ¥98.65
% Composition	**100.0%**	100.0%			100.0%			
Domestic	**176.7**	185.4	(8.7)	(4.7)	175.9	0.8	0.4	
Overseas	**26.2**	18.4	7.7	41.9	24.1	2.1	8.5	

(3) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	1st Half of FY2013	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2012	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Cost of sales	**82.4**	79.3	3.2	4.0	78.0	4.4	5.7	The sales cost ratio is worsened due to integration of plasma fractionation operations, etc.
% of Net sales	**40.6%**	38.9%			39.0%			
SG&A expenses	**90.0**	92.3	(2.4)	(2.6)	92.0	(2.0)	(2.2)	
% of Net sales	**44.4%**	45.3%			46.0%			
R&D expenses	**34.3**	34.2	0.1	0.1	35.4	(1.1)	(3.1)	
% of Net sales	**16.9%**	16.8%			17.7%			
Except R&D expenses	**55.7**	58.1	(2.4)	(4.2)	56.6	(0.9)	(1.6)	
Labor cost	**23.9**	26.0	(2.1)	(8.1)	23.8	0.1	0.2	Decrease due to integration of plasma fractionation operations, etc.
Amortization of goodwill	**5.3**	5.1	0.2	4.0	5.2	0.1	1.2	
Others	**26.6**	27.1	(0.5)	(1.8)	27.6	(1.0)	(3.8)	
Total labor cost	**41.8**	45.1	(3.3)	(7.3)	41.6	0.2	0.4	

*: Published forecasts announced on May 8, 2013 in the financial results of FY2012

(4) Non-operating Income and Loss

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	Notes
Non-operating income	**3.6**	2.3	1.2	
Interest income	**0.8**	0.8	0.0	
Dividend income	**0.5**	0.4	0.0	
Equity in earnings of affiliates	**0.3**	0.5	(0.2)	
Rent income	**1.1**	-	1.1	
Others	**1.0**	0.7	0.3	
Non-operating expenses	**1.8**	1.5	0.4	
Donations	**0.2**	0.3	0.0	
Foreign exchange loss	**-**	0.3	(0.3)	
Others	**1.6**	0.9	0.7	

(5) Extraordinary Income and Loss

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	Notes
Extraordinary income	**11.9**	1.2	10.7	
Profit on arbitration award	**11.0**	**-**	**11.0**	Reimbursed as the overpayment caused by the arbitration award of Remicade, etc
Gain on step acquisitions	**0.9**	**-**	**0.9**	
Gain on sales of property, plant and equipment	**-**	**0.6**	**(0.6)**	
Gain on transfer of business	**-**	**0.4**	**(0.4)**	FY2012: Gain on transfer of fine chemical operations
Gain on sales of investment in securities	**-**	**0.2**	**(0.2)**	
Extraordinary Loss	**0.9**	3.6	(2.8)	
Impairment loss	**0.8**	0.3	0.5	FY2013: Yoshitomi research office, etc. FY2012: Nabari No.2 training center, etc.
Loss on business integration	**-**	2.2	(2.2)	FY2012: Loss according to integration of plasma fractionation operations
Loss on valuation of investment in securities	**-**	0.7	(0.7)	
Loss on sale of investment in securities	**-**	0.1	(0.1)	
Others	**0.1**	0.3	(0.2)	

(6) Taxes

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	Notes
Income before income taxes and minority interests	**43.3**	30.7	12.6	
Income taxes-current	**14.4**	13.5	0.9	
Income taxes-deferred	**0.3**	(2.4)	2.7	
Minority interests	**0.0**	0.1	0.0	
Net Income	**28.5**	19.5	9.1	

	1st half of FY2013	1st half of FY2012
Statutory tax rate	37.9%	37.9%
Adjustment		
Non-deductible expenses	0.8%	1.3%
Non-taxable dividend income, etc.	(1.6%)	(3.2%)
Special deduction for R&D expenses	(8.0%)	(5.8%)
Amortization of goodwill	4.6%	6.2%
Elimination of dividends upon consolidation	1.4%	2.8%
Gain on step acquisitions	(0.8%)	-
Others	(0.3%)	(3.0%)
Actual tax rate	34.0%	36.2%

(7) Sales of Main Products

[Billion yen]

	1st Half of FY2013	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2012	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**199.6**	197.9	1.7	0.9	196.6	3.0	1.5
Ethical drugs domestic sales	**171.0**	176.6	(5.6)	(3.2)	169.7	1.3	0.8
Remicade	**39.0**	36.7	2.3	6.3	38.6	0.4	1.2
Ceredist	**9.1**	9.5	(0.4)	(4.1)	9.0	0.1	1.5
Maintate	**7.7**	7.0	0.8	10.9	7.5	0.2	3.0
Talion	**5.1**	5.3	(0.1)	(2.8)	5.4	(0.3)	(5.1)
Kremezin	**6.4**	6.0	0.4	6.7	6.3	0.1	1.7
Urso	**6.4**	6.8	(0.4)	(5.5)	5.9	0.5	8.3
Venoglobulin IH	**5.6**	5.5	0.1	1.8	5.7	(0.1)	(1.0)
Anplag	**5.9**	6.8	(0.9)	(13.8)	5.9	0.0	(0.5)
Radicut	**5.7**	7.0	(1.3)	(18.1)	5.0	0.7	14.3
Depas	**5.0**	5.3	(0.3)	(6.0)	4.7	0.3	5.9
Simponi	**4.4**	2.2	2.2	98.7	4.1	0.3	7.9
Lexapro	**2.4**	1.7	0.8	46.5	3.3	(0.9)	(26.2)
Herbesser	**3.5**	3.9	(0.4)	(9.4)	3.6	(0.1)	(1.5)
Tanatril	**3.2**	3.7	(0.5)	(13.2)	3.3	(0.1)	(2.7)
BIKEN Products [Vaccine]	**14.0**	12.6	1.4	10.8	12.7	1.3	10.1
Tetrabik	**3.4**	-	3.4	-	4.3	(0.9)	(20.9)
Influenza	**1.1**	1.5	(0.4)	(27.6)	1.4	(0.3)	(20.6)
Mearubik	**4.5**	5.4	(1.0)	(17.6)	2.3	2.2	94.2
Tanabe Seiyaku Hanbai Products *2	**6.7**	9.1	(2.4)	(26.4)	6.7	0.0	(0.3)
Ethical drugs overseas sales	**10.4**	10.2	0.3	2.6	10.9	(0.5)	(4.3)
Herbesser	**2.8**	2.3	0.5	20.3	2.4	0.4	15.3
Argatroban (Novastan)	**1.4**	1.4	0.0	(2.7)	0.9	0.5	50.3
Tanatril	**0.8**	0.9	0.0	(2.5)	0.9	(0.1)	(6.3)
Contracted manufacturing products *3	**2.9**	3.8	(0.8)	(22.1)	3.0	(0.1)	(2.0)
Lincensing Fee, etc.	**15.3**	7.4	7.9	107.3	13.0	2.3	17.6
Royalty from Gilenya	**14.1**	6.0	8.0	133.7	-	-	-
OTC products	**2.4**	2.8	(0.4)	(13.4)	2.7	(0.3)	(9.9)
Total pharmaceuticals	**202.1**	200.7	1.3	0.7	199.3	2.8	1.4

*1: Published forecasts announced on May 8, 2013 in the financial results of FY2012.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*3:Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of Q2 FY2013	Composition %	End of FY2012	Increase (Decrease)	Notes
Total Aseets	**881.9**	**100.0**	866.8	15.1	
Current Assets	**484.9**	**55.0**	476.7	8.2	
Cash and deposits	**33.8**	**3.8**	20.3	13.6	See Page 7, (2) Cash Flows Statement
Marketable securities	**56.5**	**6.4**	64.0	(7.5)	Decrease in commercial paper and corporate bonds, etc.
Notes and accounts receivable*1	**127.8**	**14.5**	129.9	(2.1)	
[Months/Revolution]	**[3.78]**		[3.72]	[0.06]	
Inventories	**96.2**	**10.9**	92.8	3.5	Increase in products, such as Tetrabik
Deposits	**151.8**	**17.2**	151.6	0.3	
Deferred income taxes	**9.0**	**1.0**	8.4	0.6	
Others	**9.7**	**1.1**	9.8	(0.1)	
Fixed Assets	**397.0**	**45.0**	390.1	6.9	
Property, plant and equipment	**97.6**	**11.1**	92.3	5.3	Investment for plant and equipment, 6.8; Depreciation, (3.7); Retirement, sale, impairment and others, (0.4); Increase accompanied with acquisition of Medicago, 2.5, etc.
Intangible fixed assets	**120.0**	**13.6**	104.2	15.8	Investment for information system, 1.1; Depreciation, 0.6; Record of goodwill accompanied with acquisition of Medicago, 20.0; Amortization of goodwill of the merger, (5.0)
Investment in securities	**111.8**	**12.7**	121.0	(9.2)	Decrease in government bond, decrease due to marked to market, etc.
Prepaid pension expenses	**35.7**	**4.0**	36.9	(1.2)	
Deferred income taxes	**4.2**	**0.5**	4.2	0.1	
Other investments	**27.8**	**3.1**	31.6	(3.9)	
Total Liabilities	**114.7**	**13.0**	113.9	0.8	
Current Liabilities	**86.1**	**9.8**	86.1	0.0	
Notes and accounts payable*2	**37.2**	**4.2**	38.1	(0.9)	
Short-term debt	**1.3**	**0.2**	1.2	0.2	
Current maturities of long-term debt	**0.1**	**0.0**	-	0.1	
Accounts payable, other	**16.0**	**1.8**	15.6	0.5	
Income taxes payable	**14.4**	**1.6**	16.2	(1.8)	
Other current liabilities	**17.1**	**1.9**	15.1	2.0	
Long-term Liabilities	**28.6**	**3.2**	27.7	0.9	
Long-term debts	**0.4**	**0.0**	-	0.4	
Deferred income taxes	**8.5**	**1.0**	8.4	0.2	
Accrued retirement benefits for employees	**8.9**	**1.0**	9.4	(0.6)	
Reserve for health management allowances for HIV compensation	**1.6**	**0.2**	1.6	-	
Reserve for health management allowances for SMON compensation	**2.9**	**0.3**	3.2	(0.2)	
Reserve for HCV litigation	**3.2**	**0.4**	3.6	(0.4)	
Other long-term liabilities	**3.0**	**0.3**	1.5	1.5	
Net Assets	**767.2**	**87.0**	752.9	14.3	
Shareholders' equity	**761.6**	**86.4**	744.3	17.3	
Common stock	**50.0**	**5.7**	50.0	-	
Capital surplus	**451.2**	**51.2**	451.2	-	
Retained earnings	**260.9**	**29.6**	243.6	17.3	Net income, 28.5; Payment for dividends, (11.2)
Treasury stock, at cost	**(0.5)**	**(0.1)**	(0.5)	0.0	
Accumulated other comprehensive loss	**3.2**	**0.4**	3.6	(0.4)	
Unrealized holding (losses) gains on securities	**6.6**	**0.7**	7.2	(0.6)	
Deffered (losses) gains on hedges	**1.1**	**0.1**	1.6	(0.6)	
Translation adjustments	**(4.5)**	**(0.5)**	(5.2)	0.8	
Minority interests	**2.4**	**0.3**	5.0	(2.6)	

*1: Notes and accounts receivable = Bills + Accounts receivable

*2: Notes and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	FY2012
Cash and cash equivalents at beginning of year	**58.7**	54.3	4.4	54.3
Cash flows from operating activities	**36.8**	33.3	3.5	60.6
Income before income taxes and minority interests	**43.3**	30.7	12.6	67.7
Depreciation and amortization	**4.3**	4.4	(0.1)	8.4
Loss on impairment of fixed assets	**0.8**	0.3	0.5	0.8
Amortization of goodwill	**5.3**	5.1	0.2	10.3
Increase (decrease) in accrued retirement benefit for employees	**(0.6)**	(0.6)	-	(1.2)
Decrease (increase) in prepaid pension expenses	**1.2**	2.3	(1.1)	5.2
Increase (decrease) in reserve for HCV litigation	**(0.4)**	(0.6)	0.3	1.1
Interest and dividend income	**(1.2)**	(1.2)	0.0	(2.5)
Loss (gain) on transfer of business	**-**	(0.4)	0.4	(0.4)
Profit on arbitration award	**(11.0)**	-	(11.0)	-
Loss (gain) on step acquisitions	**(0.9)**	-	(0.9)	-
Loss (gain) on sale of investment in securities	**0.0**	0.7	(0.7)	0.3
Loss (gain) on business integration	**-**	2.2	(2.2)	2.3
Decrease(increase) in notes and accounts receivable, trade	**2.1**	(0.8)	2.9	(1.9)
Decrease (increase) in inventories	**(3.4)**	(10.3)	6.9	(17.7)
Increase (decrease) in notes and accounts payable, trade	**(0.7)**	7.1	(7.8)	8.6
Increase(decrease) in accounts payable, other	**(1.2)**	(0.1)	(1.1)	(0.7)
Interest and dividends received	**1.3**	1.3	0.0	2.7
Proceeds from arbitration award	**12.2**	-	12.2	-
Income taxes paid	**(15.8)**	(7.0)	(8.7)	(17.9)
Other, net	**1.5**	0.2	1.3	(4.5)
Cash flows from investing activities	**(9.1)**	(19.0)	9.9	(35.0)
Purchase/sales etc. of marketable securities	**22.8**	(10.5)	33.4	(9.3)
Increase/decrease in time deposits	**(7.1)**	0.5	(7.7)	0.4
Increase in deposits	**(0.3)**	(0.4)	0.1	(20.7)
Increase/decrease in long-term deposits	**-**	-	-	1.9
Purchase/sales of property, plant and equipment	**(5.0)**	(1.1)	(3.9)	1.5
Purchase of intangible fixed assets	**(1.1)**	(1.0)	(0.1)	(2.1)
Purchase/sales of investment in securities	**3.0**	(2.1)	5.1	(0.5)
Purchase of investment in subsidiaries	**(3.5)**	(5.8)	2.4	(6.0)
Purchase of investment in subsidiaries resulting in consolidation scope change	**(17.9)**	-	(17.9)	-
Proceeds from transfer of business	**-**	1.4	(1.4)	1.4
Other, net	**(0.1)**	0.0	(0.1)	(1.3)
Cash flows from financing activities	**(10.9)**	(12.7)	1.8	(23.7)
Increase (decrease) in short-term debt, net	**0.0**	(1.4)	1.4	(1.2)
Increase in long-term debt	**0.4**	-	0.4	-
Cash dividends paid	**(11.2)**	(11.2)	-	(22.4)
Other, net	**0.0**	0.0	0.0	0.0
Effect of exchange rate change on cash and cash equivalents	**0.6**	0.0	0.6	2.5
Net increase (decrease) in cash and cash equivalents	**17.5**	1.6	15.9	4.4
Cash and cash equivalents at end of the year	**76.2**	55.9	20.3	58.7

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	1st Half of FY2013	1st Half of FY2012	FY2012
Cash and time deposits	33.8	15.2	20.3
Time deposits maturing after three months	(9.6)	(2.0)	(2.4)
Short-term investments in marketable securities maturing within three months of acquisition	31.5	22.5	20.6
Cash equivalents included in short-term loans receivable*	0.4	0.1	0.2
Cash equivalents included in deposits	20.1	20.1	20.1
Cash and cash equivalents in the consolidated statements of cash flows	76.2	55.9	58.7

*: Short-term loans are included in "Others, Current Assets" on page 6.

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	FY2012
Investment in property, plant and equipment / occuring basis	6.8	4.2	2.5	9.2
Investment in information systems/ occuring basis	1.1	1.0	0.0	2.2

[Billion yen]

Major investment in property, plant and equipment in 1st half of FY2013		Major investment in development of information systems in 1st half of FY2013	
Mitsubishi Tanabe Pharma	3.6	Mitsubishi Tanabe Pharma	1.0
[Construction of new head office and Kashima office building]	[0.9]		
Mitsubishi Tanabe Pharma Factory	2.3		

(4) Depreciation Costs

[Billion yen]

	1st Half of FY2013	1st Half of FY2012	Increase (Decrease)	FY2012
Property, plant and equipment	3.7	3.8	(0.1)	7.3
Intangible fixed assets	0.6	0.6	0.0	1.1

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

	Companies	Mitsubishi Tanabe Pharma Factory Ltd.	Tanabe Seiyaku Hanbai Co., Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.*	Mitsubishi Pharma (Guangzhou) Co., Ltd.*	Tianjin Tanabe Seiyaku Co., Ltd.*	P.T. Tanabe Indonesia*
Net Sales	1st Half of FY2013	**24.2**	**6.7**	**2.1**	**0.8**	**1.8**	**1.2**
	FY2012	**52.4**	**19.0**	**4.2**	**1.2**	**3.4**	**2.4**
	1st Half of FY2012	26.1	9.1	1.7	0.3	1.2	0.9
Operating Income	1st Half of FY2013	**0.3**	**0.2**	**0.2**	**(0.5)**	**0.0**	**0.2**
	FY2012	**2.2**	**1.0**	**0.3**	**(1.0)**	**0.1**	**0.3**
	1st Half of FY2012	1.7	0.5	0.2	(0.4)	0.1	0.0
Ordinary Income	1st Half of FY2013	**0.3**	**0.2**	**0.2**	**(0.6)**	**0.0**	**0.1**
	FY2012	**1.9**	**1.0**	**0.4**	**(1.0)**	**0.1**	**0.3**
	1st Half of FY2012	1.7	0.5	0.2	(0.4)	0.1	0.0
Net Income and Loss	1st Half of FY2013	**0.2**	**0.1**	**0.1**	**(0.6)**	**0.0**	**0.1**
	FY2012	**1.3**	**0.5**	**0.3**	**(1.0)**	**0.1**	**0.1**
	1st Half of FY2012	1.1	0.1	0.1	(0.4)	0.0	0.0
R&D Expenses	1st Half of FY2013	**0.6**	**-**	**-**	**0.0**	**-**	**0.0**
	FY2012	**1.1**	**-**	**-**	**0.0**	**-**	**0.0**
	1st Half of FY2012	0.6	-	-	0.0	-	0.0
Depreciation of Property, Plant and Equipment	1st Half of FY2013	**1.1**	**0.0**	**0.0**	**0.1**	**0.0**	**0.0**
	FY2012	**2.0**	**0.0**	**0.1**	**0.1**	**0.1**	**0.1**
	1st Half of FY2012	1.0	-	0.0	0.1	0.0	0.0
Total Assets	1st Half of FY2013	**62.3**	**5.3**	**3.0**	**4.4**	**3.7**	**2.5**
	FY2012	**63.7**	**8.5**	**2.7**	**4.7**	**2.4**	**2.1**
	1st Half of FY2012	63.6	7.3	2.1	3.2	1.9	1.9
Net Assets	1st Half of FY2013	**39.3**	**0.3**	**2.4**	**2.2**	**2.9**	**1.4**
	FY2012	**39.7**	**0.5**	**2.1**	**2.6**	**1.8**	**1.5**
	1st Half of FY2012	39.5	0.1	1.7	1.8	1.4	1.2
Number of Employees	1st Half of FY2013	**1409**	**171**	**126**	**440**	**446**	**488**
	FY2012	**1369**	**164**	**122**	**444**	**430**	**455**
	1st Half of FY2012	1332	166	122	463	422	446

*: In 2012, the settling days of overseas subsidiaries are changed from end of December to that of March, thus their accounting periods are for fifteen months from January, 2012 to March, 2013. In China, however, the legal settling day should be end of December and its revision is not allowed. Therefore, provisional settlement of account is used in Mitsubishi Pharma (Guangzhou) and Tianjin Tanabe Seiyaku.

3 Forecasts for FY2013 Ending March 31, 2014

(Amounts less than ￥100 million are rounded.)

Revision to the financial forecasts for FY2013

The Company has revised the forecast for FY2013 announced on May 8, 2013; sales forecast, from ¥417.0 billion to ¥419.0 billion, operating income, from ¥70.0 billion to ¥63.0 billion, ordinary income, from ¥71.5 billion to ¥65.5 billion, and net income, from ¥44.0 billion to ¥45.0 billion. For the details, see page3 of “Summary of the 2nd Quarter Financial Results for year ended March 31, 2014”.

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Net Sales	**216.2**	215.4	0.8	0.4	**419.0**	419.2	(0.2)	0.0	
Cost of Sales	**87.6**	87.1	0.5	0.5	**170.0**	166.4	3.6	2.2	
Sales cost ratio	**40.5%**	40.5%			**40.6%**	39.7%			
Gross Operatin Profit	**128.6**	128.2	0.4	0.3	**249.0**	252.8	(3.8)	(1.5)	
SG & A Expenses	**96.0**	91.5	4.5	5.0	**186.0**	183.8	2.2	1.2	
% of Net Sales	**44.4%**	42.5%			**44.4%**	43.9%			
Operating Income	**32.5**	36.7	(4.2)	(11.4)	**63.0**	69.0	(6.0)	(8.7)	
Ordinary Income	**33.3**	36.3	(3.0)	(8.2)	**65.5**	69.4	(3.9)	(5.6)	
Extraordinary Income or loss	**(7.1)**	0.7	(7.8)	-	**4.0**	(1.7)	5.7	-	
Net Income	**16.5**	22.4	(5.9)	(26.5)	**45.0**	41.9	3.1	7.4	

(2) Sales Forecasts by Segments

[Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Pharmaceuticals	**216.0**	214.0	2.0	0.9	**418.0**	414.7	3.3	0.8	
% Composition	**99.9%**	99.3%			**99.8%**	98.9%			
Domestic	**188.7**	185.7	2.9	1.6	**365.1**	369.1	(4.0)	(1.1)	
Overseas	**27.3**	28.2	(0.9)	(3.2)	**52.9**	45.6	7.3	16.1	
Other Businesses	**0.2**	1.4	(1.2)	(85.6)	**1.0**	4.5	(3.5)	(78.3)	
% Composition	**0.1%**	0.7%			**0.2%**	1.1%			
Domestic	**0.2**	0.3	(0.1)	(38.7)	**0.4**	2.4	(1.9)	(81.3)	
Overseas	**0.0**	1.1	(1.1)	(99.9)	**0.5**	2.1	(1.6)	(74.9)	
Total	**216.2**	215.4	0.8	0.4	**419.0**	419.2	(0.2)	(0.0)	Foreign sales ratio FY2012: 11.4% FY2013 estimation: 12.8%
% Composition	**100.0%**	100.0%			**100.0%**	100.0%			
Domestic	**188.9**	186.1	2.8	1.5	**365.5**	371.4	(5.9)	(1.6)	Exchange rate planned: 1US$=￥98
Overseas	**27.3**	29.3	(2.0)	(6.8)	**53.5**	47.7	5.7	12.0	

(3) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %	Notes
Cost of Sales	**87.6**	87.1	0.5	0.5	**170.0**	166.4	3.6	2.2	
Sales cost ratio	**40.5%**	40.5%			**40.6%**	39.7%			
SG & A Expenses	**96.0**	91.5	4.5	5.0	**186.0**	183.8	2.2	1.2	
% of Net sales	**44.4%**	42.5%			**44.4%**	43.9%			
R&D Expenses	**36.7**	32.3	4.4	13.7	**71.0**	66.5	4.5	6.7	
% of Net sales	**17.0%**	15.0%			**16.9%**	15.9%			
Except R&D Expenses	**59.3**	59.2	0.1	0.2	**115.0**	117.3	(2.3)	(2.0)	
Labor Cost	**24.4**	25.9	(1.5)	(5.7)	**48.3**	51.9	(3.6)	(6.9)	
Amortization of Goodwill	**5.1**	5.2	(0.1)	(1.8)	**10.4**	10.3	0.1	1.0	
Others	**29.7**	28.0	1.7	6.0	**56.3**	55.1	1.2	2.2	
Total Labor Cost	**42.0**	45.0	(3.0)	(6.6)	**83.8**	90.0	(6.2)	(6.9)	

(4) Sales Forecasts for Main Products [Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (Decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (Decrease)	Change %
Ethical drugs	**213.8**	211.5	2.4	1.1	**413.5**	409.4	4.1	1.0
Ethical drugs domestic sales	**183.5**	179.9	3.5	2.0	**354.4**	356.6	(2.1)	(0.6)
Remicade	**40.0**	36.8	3.2	8.8	**79.0**	73.5	5.5	7.5
Ceredist	**8.7**	8.9	(0.2)	(2.1)	**17.8**	18.4	(0.6)	(3.1)
Maintate	**8.5**	7.1	1.4	18.9	**16.2**	14.1	2.1	15.0
Talion	**10.5**	9.0	1.5	16.1	**15.6**	14.3	1.3	9.1
Kremezin	**6.5**	6.2	0.3	5.2	**12.9**	12.2	0.7	5.9
Urso	**6.2**	6.5	(0.3)	(5.1)	**12.6**	13.3	(0.7)	(5.3)
Venoglobulin IH	**5.9**	5.4	0.5	8.7	**11.5**	11.0	0.6	5.2
Anplag	**5.5**	6.2	(0.7)	(10.7)	**11.4**	13.0	(1.6)	(12.3)
Radicut	**4.6**	6.3	(1.7)	(27.0)	**10.3**	13.3	(3.0)	(22.3)
Depas	**4.8**	5.1	(0.3)	(5.3)	**9.8**	10.4	(0.6)	(5.7)
Simponi	**5.7**	3.0	2.7	86.9	**10.1**	5.3	4.8	91.9
Lexapro	**5.1**	2.9	2.2	76.7	**7.5**	4.6	3.0	65.6
Herbesser	**3.3**	3.7	(0.4)	(11.1)	**6.8**	7.6	(0.8)	(10.2)
Tanatril	**2.9**	3.4	(0.5)	(15.0)	**6.1**	7.1	(1.0)	(14.1)
BIKEN Products [Vaccine]	**16.7**	16.2	0.5	3.3	**30.7**	28.8	1.9	6.6
Tetrabik	**5.0**	4.5	0.5	10.4	**8.4**	4.5	3.9	85.4
Influenza	**7.1**	6.1	1.0	15.8	**8.2**	7.7	0.5	7.1
Mearubik	**1.8**	2.6	(0.8)	(31.0)	**6.3**	8.0	(1.8)	(21.9)
Tanabe Seiyaku Hanbai Products *1	**7.4**	9.9	(2.5)	(25.7)	**14.0**	19.0	(4.9)	(26.0)
Ethical drugs overseas sales	**9.9**	13.2	(3.4)	(25.4)	**20.3**	23.4	(3.1)	(13.2)
Herbesser	**2.8**	3.6	(0.9)	(23.6)	**5.6**	5.9	(0.4)	(6.6)
Argatroban (Novastan)	**1.0**	1.5	(0.5)	(35.2)	**2.3**	2.9	(0.6)	(19.5)
Tanatril	**0.9**	1.2	(0.3)	(21.2)	**1.8**	2.1	(0.3)	(13.4)
Contracted manufacturing products *2	**2.5**	3.0	(0.5)	(15.6)	**5.5**	6.8	(1.3)	(19.2)
Lincensing Fee, etc.	**18.0**	15.3	2.7	17.5	**33.3**	22.7	10.6	46.7
OTC products	**2.1**	2.5	(0.4)	(14.6)	**4.6**	5.3	(0.7)	(14.0)
Total Pharmaceuticals	**216.0**	214.0	2.0	0.9	**418.0**	414.7	3.3	0.8

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2:Active pharmaceutical ingredients and others ordered by other companies.

(5) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occuring basis	7.3	5.0	2.3	46.6	14.1	9.2	4.9	52.4
Investment for information systems/occuring basis	1.5	1.1	0.4	36.3	2.6	2.2	0.4	19.5

[Billion yen]

Major investment in property, plant and equipment in 2nd half of FY2013		Major investment for information systems in 2nd half of FY2013	
Production facilities	4.9	R&D related Systems	0.8
Facilities & equipment for R&D	1.6	Production related system	0.2
Others	0.8	Others	0.5

(6) Forecasts for Depreciation Costs

[Billion yen]

	2nd Half of FY2013 Forecasts	2nd Half of FY2012 Actual	Increase (decrease)	Change %	FY2013 Forecasts	FY2012 Actual	Increase (decrease)	Change %
Property, plant and equipment	4.5	3.5	0.9	26.7	8.2	7.3	0.9	12.1
Intangible fixed assets	0.7	0.5	0.2	32.2	1.3	1.1	0.2	16.1

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2009	FY2010	FY2011	FY2012	1st Half of FY2013	Forecast for FY2013
Net sales	404.7	409.5	407.2	419.2	202.8	419.0
Cost of sales	147.8	154.6	152.3	166.4	82.4	170.0
Gross operation profit	256.9	255.0	254.9	252.8	120.4	249.0
SG&A expenses	195.5	178.4	185.8	183.8	90.0	186.0
R&D expenses	83.1	65.8	70.2	66.5	34.3	71.0
Operating income	61.5	76.6	69.0	69.0	30.5	63.0
Ordinary income	61.6	76.7	68.8	69.4	32.2	65.5
Extraordinaly income	0.1	0.6	1.2	4.2	11.9	4.0
Extraordinaly loss	10.8	13.2	6.1	5.9	0.9	
Net income	30.3	37.7	39.0	41.9	28.5	45.0

(2) Balance Sheet

[Billion yen]

	End of FY2009	End of FY2010	End of FY2011	End of FY2012	End of 1st Half of FY2013
Total assets	796.9	818.7	819.9	866.8	881.9
Current assets	344.2	391.6	419.7	476.7	484.9
Fixed assets	452.6	427.1	400.3	390.1	397.0
Total liabilities	120.0	122.7	98.4	113.9	114.7
Current liabilities	77.8	87.7	69.6	86.1	86.1
Fixed liabilities	42.3	35.0	28.9	27.7	28.6
Net assets	676.8	696.0	721.5	752.9	767.2

(3) Other Financial Data

[Billion yen]

	FY2009	FY2010	FY2011	FY2012	1st Half of FY2013	Forecast for FY2013
Cash flows from operating activities	23.9	59.1	37.2	60.6	36.8	-
Cash flows from investing activities	(61.2)	(7.7)	(63.2)	(35.0)	(9.1)	-
Cash flows from financing activities	(17.1)	(15.4)	(17.2)	(23.7)	(10.9)	-
Investments in property, plant and equipment	8.4	10.2	7.1	9.2	6.8	14.1
Investments for development of information systems	0.8	0.8	1.2	2.2	1.1	2.6
Depreciation costs	13.3	12.4	12.5	8.4	4.3	9.5
Equity ratio (%)	84.1	84.3	87.3	86.3	86.7	-
ROE (%)	4.6	5.5	5.5	5.7	7.5	-
Net income per share (¥)	53.91	67.27	69.54	74.67	50.88	80.21
Net assets per share (¥)	1,194.79	1,230.16	1,275.85	1,333.22	1,363.33	-

(4) Number of Employees

	End of FY2009	End of FY2010	End of FY2011	End of FY2012	End of 1st Half of FY2013	Forecast for End of FY2013
Consolidated	9,266	9,198	9,180	8,835	9,197	9,088
Non-consolodated	5,186	4,957	4,826	4,850	4,913	4,896

5 Quarterly Trend

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2012					FY2013			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2012 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecasts for 2nd Half of FY2013	Forecasts for FY2013
Net sales	104.4	99.4	118.7	96.6	419.2	103.9	98.9	216.2	419.0
	24.9%	23.7%	28.3%	23.0%	100.0%	24.8%	23.6%	51.6%	100.0%
Domestic	95.6	89.8	105.2	80.8	371.4	91.4	85.3	188.9	365.5
	25.7%	24.2%	28.3%	21.8%	100.0%	25.0%	23.3%	51.7%	100.0%
Overseas	8.8	9.6	13.5	15.8	47.7	12.5	13.7	27.3	53.5
	18.4%	20.2%	28.3%	33.1%	100.0%	23.4%	25.5%	51.1%	100.0%
Pharmaceuticals	101.9	98.8	118.2	95.8	414.7	103.4	98.6	216.0	418.0
	24.6%	23.8%	28.5%	23.1%	100.0%	24.7%	23.6%	51.7%	100.0%
Domestic	93.7	89.7	105.1	80.7	369.1	91.3	85.1	188.7	365.1
	25.4%	24.3%	28.5%	21.9%	100.0%	25.0%	23.3%	51.7%	100.0%
Overseas	8.2	9.2	13.1	15.1	45.6	12.1	13.5	27.3	52.9
	18.0%	20.1%	28.8%	33.1%	100.0%	22.9%	25.5%	51.6%	100.0%
Others	2.5	0.6	0.6	0.8	4.5	0.5	0.3	0.2	1.0
	54.9%	13.9%	12.5%	18.7%	100.0%	50.8%	28.6%	20.7%	100.0%
Domestic	1.9	0.1	0.2	0.2	2.4	0.1	0.1	0.2	0.4
	80.4%	5.8%	7.3%	6.6%	100.0%	29.3%	25.3%	45.4%	100.0%
Overseas	0.6	0.5	0.4	0.7	2.1	0.4	0.2	0.0	0.5
	26.7%	23.0%	18.2%	32.2%	100.0%	68.5%	31.3%	0.2%	100.0%
Cost of sales	40.6	38.6	47.5	39.7	166.4	43.5	38.9	87.6	170.0
Sales Cost Ratio	38.9%	38.8%	40.0%	41.0%	39.7%	41.9%	39.3%	40.5%	40.6%
Gross operating profit	63.7	60.8	71.3	57.0	252.8	60.4	60.0	128.6	249.0
	25.2%	24.1%	28.2%	22.5%	100.0%	24.3%	24.1%	51.6%	100.0%
SG&A expenses	44.9	47.4	44.7	46.8	183.8	44.2	45.8	96.0	186.0
	24.4%	25.8%	24.3%	25.5%	100.0%	23.7%	24.6%	51.6%	100.0%
R&D expenses	16.9	17.3	17.0	15.3	66.5	17.6	16.7	36.7	71.0
	25.4%	26.0%	25.5%	23.0%	100.0%	24.7%	23.6%	51.7%	100.0%
Non-R&D expenses	28.0	30.1	27.7	31.5	117.3	26.6	29.1	59.3	115.0
	23.9%	25.7%	23.6%	26.9%	100.0%	23.1%	25.3%	51.6%	100.0%
Labor costs	12.9	13.0	12.5	13.5	51.9	11.9	12.0	24.4	48.3
	24.9%	25.1%	24.0%	25.9%	100.0%	24.5%	24.8%	50.6%	100.0%
Amortization of goodwill	2.5	2.5	2.6	2.6	10.3	2.6	2.7	5.1	10.4
	24.6%	24.6%	25.5%	25.3%	100.0%	25.0%	25.6%	49.4%	100.0%
Others	12.5	14.5	12.6	15.5	55.1	12.1	14.4	29.7	56.3
	22.8%	26.3%	22.8%	28.1%	100.0%	21.6%	25.6%	52.8%	100.0%
Operating income	18.8	13.4	26.6	10.1	69.0	16.2	14.2	32.5	63.0
	27.3%	19.4%	38.6%	14.7%	100.0%	25.8%	22.6%	51.7%	100.0%
Ordinary income	19.6	13.5	27.0	9.3	69.4	17.1	15.1	33.3	65.5
	28.3%	19.4%	38.9%	13.3%	100.0%	26.0%	23.1%	50.8%	100.0%
Net income	10.8	8.7	15.8	6.6	41.9	10.4	18.1	16.5	45.0
	25.8%	20.7%	37.6%	15.9%	100.0%	23.1%	40.3%	36.6%	100.0%

The each figure (excluding Cost of sales) in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2012					FY2013			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2012 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecasts for 2nd Half of FY2013	Forecasts for FY2013
Ethical drugs	100.6	97.4	116.7	94.8	409.4	102.3	97.3	213.8	413.5
	24.6%	23.8%	28.5%	23.1%	100.0%	24.7%	23.5%	51.7%	100.0%
Ethical drugs domestic sales	90.5	86.1	102.0	78.0	356.6	88.5	82.4	183.5	354.4
	25.4%	24.1%	28.6%	21.9%	100.0%	25.0%	23.3%	51.8%	100.0%
Remicade	17.9	18.8	19.8	17.0	73.5	19.2	19.9	40.0	79.0
	24.4%	25.6%	27.0%	23.1%	100.0%	24.3%	25.1%	50.6%	100.0%
Ceredist	5.0	4.5	5.0	3.9	18.4	4.7	4.4	8.7	17.8
	27.2%	24.6%	27.0%	21.3%	100.0%	26.4%	24.8%	48.8%	100.0%
Maintate	3.6	3.3	4.0	3.2	14.1	4.0	3.8	8.5	16.2
	25.8%	23.6%	28.1%	22.6%	100.0%	24.5%	23.2%	52.4%	100.0%
Talion	3.1	2.2	3.7	5.3	14.3	2.7	2.4	10.5	15.6
	21.3%	15.5%	25.8%	37.3%	100.0%	17.5%	15.3%	67.2%	100.0%
Kremezin	3.1	2.9	3.5	2.7	12.2	3.2	3.2	6.5	12.9
	25.7%	23.6%	28.7%	22.0%	100.0%	25.1%	24.5%	50.4%	100.0%
Urso	3.5	3.3	3.7	2.9	13.3	3.3	3.1	6.2	12.6
	26.3%	24.6%	27.6%	21.6%	100.0%	26.1%	24.6%	49.2%	100.0%
Venoglobulin IH	2.9	2.7	3.2	2.2	11.0	2.9	2.7	5.9	11.5
	26.1%	24.4%	29.2%	20.3%	100.0%	25.2%	23.7%	51.1%	100.0%
Anplag	3.7	3.1	3.5	2.7	13.0	3.1	2.8	5.5	11.4
	28.3%	24.3%	27.0%	20.5%	100.0%	27.2%	24.4%	48.4%	100.0%
Radicut	3.7	3.3	3.7	2.6	13.3	3.0	2.7	4.6	10.3
	28.0%	24.6%	27.7%	19.8%	100.0%	28.8%	26.6%	44.6%	100.0%
Depas	2.8	2.5	2.8	2.2	10.4	2.6	2.4	4.8	9.8
	26.7%	24.4%	27.4%	21.5%	100.0%	26.2%	24.7%	49.1%	100.0%
Simponi	1.0	1.2	1.6	1.5	5.3	2.1	2.4	5.7	10.1
	19.7%	22.5%	29.5%	28.3%	100.0%	20.4%	23.3%	56.3%	100.0%
Lexapro	0.8	0.9	1.4	1.5	4.6	1.0	1.4	5.1	7.5
	16.5%	20.0%	31.0%	32.5%	100.0%	13.7%	18.7%	67.7%	100.0%
Herbesser	2.1	1.8	2.1	1.6	7.6	1.9	1.7	3.3	6.8
	27.7%	23.7%	27.9%	20.8%	100.0%	27.0%	24.7%	48.2%	100.0%
Tanatril	2.0	1.7	2.0	1.5	7.1	1.7	1.5	2.9	6.1
	27.7%	24.3%	27.6%	20.5%	100.0%	27.7%	24.8%	47.5%	100.0%
BIKEN products [vaccines]	6.1	6.5	11.4	4.8	28.8	8.8	5.2	16.7	30.7
	21.3%	22.6%	39.5%	16.6%	100.0%	28.6%	16.9%	54.4%	100.0%
Tetrabik	-	-	2.7	1.8	4.5	2.9	0.5	5.0	8.4
	-	-	59.3%	40.7%	100.0%	34.5%	6.0%	59.5%	100.0%
Influenza	0.0	1.6	6.8	(0.7)	7.7	(0.1)	1.2	7.1	8.2
	(0.5%)	20.5%	88.7%	(8.7%)	100.0%	(0.7%)	14.2%	86.5%	100.0%
Mearubik	3.4	2.1	0.7	1.9	8.0	3.2	1.2	1.8	6.3
	41.9%	25.6%	9.2%	23.3%	100.0%	51.8%	19.5%	28.7%	100.0%
Tanabe Seiyaku Hanbai products *1	4.8	4.2	5.5	4.3	19.0	3.5	3.2	7.4	14.0
	25.5%	22.3%	29.2%	22.9%	100.0%	25.0%	22.6%	52.4%	100.0%
Ethical drugs overseas sales *2	4.5	5.6	5.0	8.2	23.4	5.1	5.3	9.9	20.3
	19.5%	24.0%	21.6%	35.0%	100.0%	25.3%	26.1%	48.6%	100.0%
Herbesser	1.1	1.2	1.1	2.5	5.9	1.5	1.3	2.8	5.6
	19.3%	19.4%	19.1%	42.2%	100.0%	26.3%	23.6%	50.2%	100.0%
Argatroban (Novastan)	0.7	0.7	0.5	1.0	2.9	0.7	0.7	1.0	2.3
	24.8%	23.5%	17.2%	34.6%	100.0%	28.3%	30.0%	41.7%	100.0%
Tanatril	0.5	0.4	0.4	0.8	2.1	0.5	0.4	0.9	1.8
	21.9%	20.2%	20.6%	37.3%	100.0%	26.2%	21.1%	52.7%	100.0%
Contracted manufacturing products *3	1.7	2.1	1.3	1.7	6.8	1.5	1.4	2.5	5.5
	25.3%	30.2%	18.8%	25.6%	100.0%	27.5%	26.0%	46.4%	100.0%
Lincensing fee, etc.	3.8	3.6	8.4	6.9	22.7	7.1	8.2	18.0	33.3
	16.7%	15.9%	37.2%	30.3%	100.0%	21.4%	24.6%	54.0%	100.0%
OTC products	1.4	1.5	1.5	1.0	5.3	1.1	1.3	2.1	4.6
	25.6%	27.5%	27.8%	19.1%	100.0%	25.0%	28.4%	46.5%	100.0%
Total pharmaceuticals	101.9	98.8	118.2	95.8	414.7	103.4	98.6	216.0	418.0
	24.6%	23.8%	28.5%	23.1%	100.0%	24.7%	23.6%	51.7%	100.0%

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2: In 2012, the settling days of overseas subsidiaries are changed from end of December to end of March, thus their accounting periods are for fifteen months from January, 2012 to March, 2013.

*3: Active pharmaceutical ingredients and others ordered by other companies.

6 State of New Product Development (As of October 30, 2013)

1. New Drugs

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Filed (May, 2013)	In-house
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Taiwan	Filed (Jan., 2013)	US:Vertex
		Korea	Phase 1	
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Japan	Phase 2b/3	Hungary: Gedeon Richter
MT-4666	α7nACh receptor agonist (Dementia of Alzheimer's type)	Japan	Phase 2	US: EnVivo
MT-9938 (Nalfurafine)	κ-opioid receptor agonist (Refractory pruritus in Hemodialysis patients)	US, Canada	Phase 2	Japan:Toray
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
		Japan	Phase 2	
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
		Japan	Phase 1	
	(Psoriasis)	Europe	Phase 2	
	(Inflammatory bowel disease)	Europe	Phase1	
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MP-157	Angiotensin Type 2 receptor agonist (Hypertension)	Europe	Phase 1	In-house

2. Additional Indications

Product name (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	Japan	sNDA filed (Feb., 2013)	In-house	
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Japan	Phase 3	In-house	
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Japan	Phase 3	Japan: Ube Industries	
	(Pediatric atopic dermatitis)		Phase 3		
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2])	Japan	Phase 3	US:Vertex	
	(Chronic hepatitis C, [combination with Pegasys])		Phase 3		
	(Chronic hepatitis C, [combination with Feron])		Phase 3		
Remicade (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Refractory Kawasaki disease*)	Japan	Phase 3	US:Janssen Biotech	
	(Behcet's disease with special lesions*)		Phase 3		
	(Pediatric Crohn's disease)		Phase 3		
	(Pediatric ulcerative colitis)		Phase 3		
	(Psoriasis: increased dose)		Phase 3		
Imusera (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study	P3	In-house	Co-developed with Novartis Pharma, licensed to Novartis overseas
BindRen (Colestilan[INN])	Non-absorbed phosphate binder (Pediatric hyperphosphatemia)	Europe	Phase 3	In-house	
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Japan	Phase 2	In-house	
	Non-absorbed phosphate binder (Hyperphosphatemia)	Japan	Phase 1		

* Orphan drug designated

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	Europe	MAA filed (Jul., 2012)	US: Janssen Pharmaceuticals
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR)	US	NDA filed (Feb., 2013)	
	(Type2 diabetes mellitus / fixed dose combination with metformin, IR)	Europe	MAA filed (Mar., 2013)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	NDA filed (Sep., 2013)	Korea: Handok Pharmaceuticals
FTY720 (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Multinational study	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
T-0047 (Firategrast)	Cell adhesion inhibitor [α4β7/α4β1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 1/2	Japan: Kyowa Hakko Kirin
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma/Sidem
TT-138	β3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	Phase 1	US: SONKEI Pharmaceuticals
Y-803	Bromodomain inhibitor (Hematological cancer)	US, Europe	Phase 1	Switzerland: OncoEthix (Development code: OTX015)

4. Changes Since Previous Announcement on July 31, 2013

(1) In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of July 31, 2013	As of October 30, 2013
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Japan	Phase 1	Phase 2
MT-1303	S1P receptor functional antagonist (Psoriasis)	Europe	None	Phase 2
	(Inflammatory bowel disease)	Europe	None	Phase 1
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Discontinued

(2) Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of July 31, 2013	As of October 30, 2013
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	NDA filed (Sep., 2013)
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 1	Phase 1/2

5. Additional Information for State of New Product Development (as of October 30, 2013)

(1) New Drugs

Development code (Generic name)	Information
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. It was filed for type2 diabetes mellitus in Japan.
MP-424 (Telaprevir)	MP-424 is NS3-4A protease inhibitor, licensed from Vertex (US). It was filed in Taiwan, and Phase1 is conducted in Korea. It was launched as a treatment for chronic hepatitis C in Japan under the brand name, TELAVIC®.
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon Richter (Hungary). Clinical stage is Phase 2b/3 for schizophrenia in Japan.
MT-4666	MT-4666 is an α7 nACh receptor agonist, licensed from EnVivo(US). Clinical stage is Phase 2 for dementia of Alzheimer's type.
MT-9938 (Nalfurafine)	MT-9938 is a κ-opioid receptor agonist, licensed from Toray (Japan). Clinical stage is Phase 2 for refractory pruritus in the US.
MP-513 (Teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. Clinical stages in the US and Europe are Phase 1 and Phase 2, respectively. It has been marketed in Japan for the treatment of type2 diabetes mellitus in September 2012, under the brand name of TENELIA®.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase2 for diabetic nephropathy in Europe and Japan.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist. Clinical stage is Phase1 in Japan, and Phase2 for Multiple sclerosis in EU, is Phase2 for Psoriasis in EU, is Phase1 for inflammatory bowel diseasein EU as a succesor of Imusera/Gilenya.
GB-1057(Recombinant human serum albumin)	GB-1057 is a recombinant human serum albumin. Clinical stage is Phase 1 as a stabilizing agent in the US.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect. Clinical stages are Phase 1 in the US and Canada .
MP-157	MP-157 is an angiotensin type2 receptor agonist. Clinical stage is Phase 1 in Europe.

(2) Additional Indications

Product name (Generic name)	Information
Tenelia (Teneligliptin)	Tenelia is developed for the treatment of type2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP-4), thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in September, 2012. An application for additional combination therapy was filed.
Radicut (Edaravone)	(Amyotrophic lateral sclerosis [Orphan drug designated in June, 2005]) Radicut is a free radical scavenger. In 2001, it was launched for improvement neurological symptoms at the acute stage of cerebral infarction, interference with activities of daily living and functional disability. Clinical stage is Phase 3 for ALS.
Talion (Bepotastine)	Talion was launched as an anti-allergic agent for adult in 2000. (Pediatric allergic rhinitis) Clinical stage is Phase 3.
	(Pediatric atopic dermatitis) Clinical stage is Phase 3.
Telavic (Telaprevir)	Telavic was launched as a treatment for chronic hepatitis C in 2011. (Chronic hepatitis C [genotype2]) Clinical stage is Phase 3.
	(Chronic hepatitis C, [combination with Pegasys]) Clinical stage is Phase 3.
	(Chronic hepatitis C, [combination with Feron]) Clinical stage is Phase 3.
Remicade (Infliximab[recombinant])	Remicade is an anti-human TNFα monoclonal antibody. It was launched as a treatment for Crohn's disease in 2002, followed by rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, and ulcerative colitis. (Refractory Kawasaki disease [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Behcet's disease with special lesions [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Pediatric Crohn's disease) Clinical stage is Phase 3.
	(Pediatric ulcerative colitis) Clinical stage is Phase 3.
	(Psoriasis: inceased dose) Clinical stage is Phase 3.
Imusera (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. Imusera had been jointly developed with Novaltis Pharma for the domestic market. Imusera was launched as a treatment for multiple sclerosis in 2011. (Chronic inflammatory demyelinating polyradiculoneuropathy) Clinical stage is Phase 3, multinational study. It has been jointly developed with Novaltis Pharma for the domestic market.
BindRen Colestilan[INN]	Cholebine is a bile acid eliminant. The product has been marketed in Japan for the treatment of hypercholesterolemia from 1999, under the brand name of CHOLEBINE®. (Pediatric hyperphosphatemia) Clinical stage is Phase 3. It has been launched for the treatment of hyperphosphatemia in dyalisis patients in Germany and Austraria.
Cholebine (Colestimide[JAN])	Cholebine is a bile acid eliminant. It was launched as a treatment for hypercholesterolemia in 1999. (Type 2 diabetes mellitus) Clinical stage is Phase 2.
	(Hyperphosphatemia) Clinical stage is Phase 1.

(3) Licensing-out

Development code (Generic name)	Information
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. In Europe, MAA was submitted by Janssen Pharmaceuticals in June 2012. It has been marketed in the US for the treatment of type2 diabetes mellitus, under the brand name of INVOKANA™. NDA, in the US in Dec. 2012, and MAA, in Europe in March 2013, were submitted for the fixed dose combination with metformin, IR. Phase 2 clinical trials in obesity in Europe and the US are completed.
MP-513 (Teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. In Korea, NDA was submitted by Handok in Kore in September 2013.
FTY720 (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It was launched as a treatment for multiple sclerosis under the brandname of Imusera by Mitsubishi Tanabe Pharma in Japan. It is also marketed under the brand name of Gilenya by Novartis. (Chronic inflammatory demyelinating polyradiculoneuropathy) Multinational study is Phase 3, co-development with Novartis Pharma in Japan.
T-0047 (Firategrast)	T-0047 inhibits the cell adhesion and cell migration processes of white blood cells in inflammatory region. Phase 2 is conducted by GSK in Europe, etc.
MKC-242	MKC-242 is a serotonin 1A receptor agonist, used to treat psychiatric disorders such as anxiety and depression. This compound is expected to express rapid onset with low possibility of dependency. MediciNova (US) is conducting Phase 2 for insomnia.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscles. Clinical stage is Phase 2 in Japan by Senju Pharmaceutical.
MT-210	MT-210 is a 5-HT2A/ Sigma 2 receptor antagonist. Clinical stage is Phase 2 in Europe by Cyrenaic (France).
TA-7906	TA-7906 is a PDE4 inhibitor. Clinical stage is Phase 2 for the treatment of atopic dermatitis in Japan by Maruho.
MCC-847 (Masilukast)	Leukotriene D4 receptor antagonist. Clinical stage is Phase 2 for the treatment of asthma in Korea by SAMA Pharma (Korea).
MT-4580	Ca sensing receptor agonist. Clinical stage is Phase 1/2 for the treatment of secondary hyperparathyroidism in Hemodialysis patients in Japan by Kyowa Hakko Kirin (Japan).
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long half-life. It is expected that this compound could reveal rapid improvement for non-erosive reflux disease. Sidem Pharma, a subsidiary of Negma, is conducting phase 1 in Europe.
TT-138	TT-138 is a β3 receptor agonist used to treat pollakiuria and urinary incontinence. Phase 1 is conducted by MediciNova in the US.
Wf-516	SSRI / 5HT1A receptor antagonists. Clinical stage is Phase 1 for the treatment of depression in Europe by SONKEI Pharmaceuticals (US).
Y-803	Bromodomain inhibitor. Clinical stage is Phase 1 for the treatment of hematological cancer in the US and Europe by OncoEthix (Switzerland).

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of 1st Half of FY2013	End of FY2012	Increase (Decrease)	Notes
Consolidated subsidiaries	**31**	28	3	Increase: MTPC Holdings Canada, Medicago, Medicago USA, Medicago R&D Decrease: Tanabe Europe
Non-consolidated subsidiaries	**1**	1	0	
Affiliated companies	**4**	3	1	Increase: Tanabe Europe (not accounted for by equity method)
Total	**36**	32	4	

(2) Consolidated Subsidiaries [As of September 30, 2013]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Mitsubishi Tanabe Pharma Factory Ltd.	1,130	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Mitsubishi Pharma (Guangzhou) Co., Ltd.	US$23,500,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
4	Tianjin Tanabe Seiyaku Co., Ltd.	US$16,230,000	75.4	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
5	Yoshitomiyakuhin Corporation	385	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
6	Bipha Corporation	100	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
7	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	400	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
8	Tanabe Seiyaku Hanbai., Ltd.	169	100.0	[-]	End of Mar.	Sale of generic pharmaceuticals, etc.
9	Tanabe R&D Service Co., Ltd.	44	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
10	Tanabe Total Service Co., Ltd.	90	100.0	[-]	End of Mar.	Real estate management, etc.
11	Benesis Corporation	100	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
12	MP-Logistics Corporation	95	65.0	[-]	End of Mar.	Distribution, warehouse operations
13	MP Healthcare Venture Management, Inc.	US$100	100.0	[-]	End of Mar.	Investments in bio-ventures
14	Mitsubishi Tanabe Pharma Holdings America, Inc.	US$166	100.0	[-]	End of Mar.	Management of group companies in US
15	Mitsubishi Tanabe Pharma Development America, Inc.	US$100	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
16	Tanabe Research Laboratories U.S.A., Inc.	US$3,000,000	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
17	Tanabe U.S.A., Inc.	US$1,400,000	100.0	[100.0]	End of Mar.	Sale of chemicals, etc.
18	Mitsubishi Tanabe Pharma America, Inc.	US$100	100.0	[100.0]	End of Mar.	Sale of pharmaceuticals
19	MTPC Holdings Canada Inc.	CAD 192,709,000	100.0	[-]	End of Dec.	Investments in Medicago Group
20	Medicago Inc.	CAD 158,567,000	60.0	[54.3]	End of Dec.	Manufacture and sale of vaccines
21	Medicago USA Inc.	US$99	60.0	[54.3]	End of Dec.	Manufacture of vaccines
22	Medicago R&D Inc.	CAD 500	60.0	[54.3]	End of Dec.	R&D of vaccines
23	Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.	US$1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
24	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
25	Taiwan Tanabe Seiyaku Co., Ltd.	NT$90,000,000	65.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
26	Tai Tien Pharmaceuticals Co., Ltd.	NT$20,000,000	65.0	[-]	End of Mar.	Sale of pharmaceuticals
27	P.T. Tanabe Indonesia	US$2,500,000	99.6	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
28	Mitsubishi Pharma Europe Ltd.	£4,632,000	100.0	[-]	End of Mar.	R&D of pharmaceuticals
29	Mitsubishi Pharma Deutschland GmbH	EUR 25,000	100.0	[100.0]	End of Mar.	Sale of pharmaceuticals

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method [As of September 30, 2013]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	API Corporation	4,000	47.7	[-]	End of Mar.	Manufacture and sale of API, etc.
2	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	End of September, 2013	End of March, 2012
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**425,613**	424,977
Number of shares outstanding at the end of the period	**560,992,303**	560,992,939
Average number of the company's own share in the period	**425,316**	423,959
Average number of shares outstanding in the period	**560,992,600**	560,993,957

(2) Status of Major Shareholders

Rank	Name of Shareholders	End of September, 2013		End of March, 2013		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	Japan Trustee Services Bank, Ltd.	24,197	4.31%	2	31,890	5.68%
3	The Master Trust of Japan, Ltd.	23,310	4.15%	3	26,640	4.75%
4	Nippon Life Insurance Company	13,611	2.42%	4	15,116	2.69%
5	Nipro Corporation	7,642	1.36%	5	7,642	1.36%
6	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	6	7,254	1.29%
7	JP Morgan Chase Bank, N.A., 385147	7,100	1.26%	7	7,100	1.26%
8	Employee Stock Ownership Plan	4,849	0.86%	8	4,747	0.85%
9	SIX SIS Ltd.	4,670	0.83%	21	2,064	0.37%
10	Tokyo Marine & Nichido Fire Insurance Co., Ltd.	4,175	0.74%	10	4,175	0.74%

(3) Ownership and Distribution of Shares

	End of September, 2013			End of March, 2013		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	82	91,099	16.23%	81	104,341	18.59%
Foreign corporations and others	382	93,803	16.71%	388	86,473	15.41%
Individuals and others	20,888	33,018	5.88%	16,331	29,397	5.24%
Other corporations	294	338,945	60.38%	286	339,197	60.43%
Securities firms	48	4,444	0.79%	44	1,900	0.34%
Total	21,694	561,311	100.00%	17,130	561,311	100.00%
Less than trading unit	-	106	-	-	106	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stocks (425 thousands shares at the end of September, 2013 and 424 thousands shares at the end of March, 2013)

(4) Trend of Divinded and Stock Price

	FY2009	FY2010	FY2011	FY2012	1st Half of FY2013	FY2013 Estimate
Dividends per share (yen)	28	28	35	40	20	40
Dividend payout ratio(%)	51.9	41.6	50.3	53.6	-	49.9
(prior to amortization of goodwill)	(39.0)	(32.9)	(40.0)	(43.2)	(-)	(40.8)
Stock price at the end of FY	1,320	1,350	1,161	1,445	1,377	-
Market capitalization (billion yen)	7,411	7,579	6,518	8,112	7,731	-

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNFα monoclonal antibody

Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addtion, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively.
Origin: Jannsen Biotech

Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration

Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was launched in October 2009.

Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias)

Maintate is a representative β -blocker used in more than 100 countries around the world. It exhibits high selectivity for β 1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and there is evidence for its cardioprotective action. In addition to the indication of chronic heart failure which was approved in May, 2011, the indication of atrial fibrillation has been newly approved in June, 2013 . Maintate is the only β-blocker with both indications of chronic heart failure and atrial fibrillation in Japan.
Origin: Merck Serono (Germany)

Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders

Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007.
Origin: Ube Industries

Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure

Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC.
Origin, Manufacturer and distributor: Kureha

Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions

Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.

Venoglobulin IH (Human immunoglobulin)	Launch: Jan. 1992	Category	Plasma derivatives

Venoglobulin IH is intravenous human immunoglobulin derived from donated plasma in Japan. It shows high efficacy on serious infectious diseases in combined administration with an anti-bacterial agent due to its opsonic, immuno-bacteriolytic and antibody-dependent cytotoxic effects and neutralizing effects on toxics and viruses. In October 2010 the indication of improvement of muscle weakness associated with polymyositis or dermatomyositis, in February 2011 the indication of generalized myasthenia gravis (only in case of insufficient response to steroids or immunosuppressants) , and in October 2011 the indication of improvement of muscle weakness associated with chronic inflammatory demyelinating polyneuropathy (including polydomous motion-neuropathy) were all approved. In addition, in August 2013, the indication of pemphigus (only in case of insufficient response to steroids) has been approved. Those additional indications are expected to contribute better QOL for the patients.

Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)

Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.

Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)

Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010.

Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent

Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.

Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNFα monoclonal antibody

Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage), and co-marketed with Janssen Pharmaceutical. It shows a long acting efficacy by subcutaneous injection once every four weeks, and currently is under development for the ulcerative colitis by Janssen Pharmaceutical.
Origin: Janssen Biotech

Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective sertonin reuptake inhibitor (SSRI)

Lexapro is a selective serotonin reuptake inhibitor with high selectivity of serotonin transporter, and approved in more than 97 countries and regions. By having good efficacy and tolerability, in addition to simple administration, it is expected to contribute to the improvement of medication adherence for patients with depression.
Origin: H. Lundbeck, Manufacturer and distributor: Mochida Pharmaceutical

Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)

Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.

Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE inhibitor (Treatment of hypertension)

Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in January 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.

TETRABIK (Absorbed Diphtheria-purified Pertussis-tetanus inactivated polio	Launch: Oct. 31. 2012	Category	Prevention of Diphtheria, Pertussis, Tetanus and polio

TETRABIK is a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus. It is used at 1st term (initial 3 times) and 1st term (additional 1 time), in total 4 times, of the regular vaccination. By using TETRABIK, It is expected to avoid the very rare occurrence of paralytic symptoms similar to those in natural polio due to live-attenuated oral polio vaccine.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella

Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik, which is used at the 1st term and the 2nd term of its regular vaccination. By both reducing the number of injections and relieving physical pain on people to be vaccinated, It is expected to contribute enhancement of immunization rate for measles and rubella in Japan.
Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)

News Releases

The major news releases after April 2013 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/release/index.php)

Date	Contents
April 1, 2013	U.S. FDA Approves Canagliflozin (TA-7284) for the Treatment of Adult Patients with Type 2 Diabetes
April 1, 2013	Transfer of Tanabe Europe's shares
April 3, 2013	Launch of BindRen for Treatment of Hyperphosphatemia in Germany and Austria
May 27, 2013	New Drug Application Filed in Japan for TA-7284 (Canagliflozin) To Treat Patients with Type 2 Diabetes
June 14, 2013	Approval for Additional Indication for Atrial Fibrillation (Tachycardiac) MAINTATE Tablets: Selective β1 Blocker
June 27, 2013	VIVUS gains MAA approval for TA-1790 in the EU
July 12, 2013	Notice regarding the acquisition of Medicago Inc.
August 1, 2013	Notice regarding the reorganization of Mitsubishi Tanabe Pharma Factory Ltd.'s domestic production sites and the conclusion of a basic agreement regarding the transfer of its Ashikaga Plant
August 6, 2013	Tianjin Tanabe Seiyaku to Construct New Production Facility in China
August 8, 2013	Notice Regarding Arbitration Award in Dispute with Janssen Biotech, Inc.
September 9, 2013	Tanabe Indonesia to Construct New Production Facility in Indonesia
September 19, 2013	Notice Regarding Completion of Acquisition of Shares of Medicago, Inc., a Pharmaceutical Company Based in Canada, Which Has Become a Subsidiary of Mitsubishi Tanabe Pharma
September 19, 2013	Mitsubishi Tanabe Pharma to Open Singapore Office
September 30, 2013	Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law of Japan